XNASVRPX
Market cap2mUSD
Dec 24, Last price
0.32USD
1D
-6.89%
1Q
-54.14%
IPO
-99.47%
Name
Virpax Pharmaceuticals Inc
Chart & Performance
Profile
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | ||||||
Revenues | ||||||
Cost of revenue | 16,940 | 21,845 | 12,026 | |||
Unusual Expense (Income) | ||||||
NOPBT | (16,940) | (21,845) | (12,026) | |||
NOPBT Margin | ||||||
Operating Taxes | (194) | 93 | ||||
Tax Rate | ||||||
NOPAT | (16,940) | (21,651) | (12,118) | |||
Net income | (15,190) -29.21% | (21,456) 76.61% | (12,149) 170.72% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 58,020 | |||||
BB yield | -144.39% | |||||
Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (9,142) | (18,995) | (36,842) | |||
Cash flow | ||||||
Cash from operating activities | (9,854) | (17,847) | (14,543) | |||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | 51,330 | |||||
FCF | (16,940) | (21,008) | (15,822) | |||
Balance | ||||||
Cash | 9,142 | 18,995 | 36,842 | |||
Long term investments | ||||||
Excess cash | 9,142 | 18,995 | 36,842 | |||
Stockholders' equity | (59,544) | (44,355) | (22,704) | |||
Invested Capital | 61,478 | 60,935 | 60,181 | |||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 1,171 | 1,171 | 1,171 | |||
Price | 3.20 -48.56% | 6.22 -81.86% | 34.30 | |||
Market cap | 3,749 -48.56% | 7,288 -81.86% | 40,182 | |||
EV | (5,392) | (11,707) | 3,340 | |||
EBITDA | (16,940) | (21,845) | (12,026) | |||
EV/EBITDA | 0.32 | 0.54 | ||||
Interest | 194 | 93 | ||||
Interest/NOPBT |